Renalase peptides reduce pancreatitis severity in mice

Area of Science:

• Biomedical research
• Gastroenterology
• Pharmacology

Background:

• Acute pancreatitis is a serious pancreatic inflammatory condition lacking specific treatments.
• Renalase, a protein with anti-inflammatory and prosurvival functions, shows promise for therapeutic intervention.
• The active site (RP220) of renalase contains its therapeutic properties.

Purpose of the Study:

• To investigate the therapeutic efficacy of renalase peptides in clinically relevant acute pancreatitis models.
• To evaluate the impact of renalase peptides on pancreatitis-induced tissue damage and inflammation.

Main Methods:

• Utilized two preclinical models: post-endoscopic retrograde cholangiopancreatography (ERCP) and severe cerulein-induced pancreatitis in mice.
• Administered renalase peptides prophylactically or therapeutically.
• Assessed early pancreatitis markers (edema, amylase, zymogens) and later histologic injury and inflammation.

Main Results:

• Renalase peptides significantly reduced histologic damage, including inflammation, necrosis, and overall injury in both models.
• Demonstrated a significant reduction in bone marrow-derived inflammation, neutrophils, and macrophages.
• Observed significant injury reduction in the severe cerulein model with or without pretreatment.

Conclusions:

• Renalase peptides retain the anti-inflammatory and prosurvival properties of recombinant renalase.
• These peptides effectively mitigate acute pancreatitis severity in preclinical settings.
• Renalase peptides represent promising candidates for future therapeutic development for acute pancreatitis.